Clinical trials: sponsored by Galderma R&D
Acne Vulgaris
Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris
The purpose of this study is to demonstrate the non-inferior efficacy of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel when compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in Subjects with acne vulgaris after a 12-week…
- Trial name
- NCT00441415
- Testing
- Adapalene BPO
- Where
- 4 sites in United States
- Volunteers
- 272 people
- Sponsor
- Galderma R&D
Onychomycosis
Single-blind Evaluation of Device to Nail Micro-drilling in Onychomycosis
Based on manufacturer testing, no major difference in drilling condition is expected in this study compared to the drilling conditions previously established.
- Trial name
- NCT00941317
- Testing
- Pathformer (micro-drilling device)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Galderma R&D
Actinic Keratosis
Metvix Daylight PDT in Actinic Keratosis
Prospective non-interventional study conducted in Australia, Brazil, Mexico and Europe to evaluate clinical practice with Metvix Daylight PDT in the treatment of mild to moderate actinic keratosis of the face/scalp and to assess…
- Trial name
- SESAME (NCT02674048)
- Testing
- Metvix
- Where
- 7 sites in Australia, France and 5 more
- Volunteers
- 406 people
- Sponsor
- Galderma R&D
Foot Dermatoses
Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1%
The main objective of this study is to compare subject adherence and satisfaction for two modes of treatment toenails infection (Onychomycosis) with Loceryl Nail Lacquer (Loceryl NL) and a Fungal Nail Treatment Set containing…
- Trial name
- OPEN (NCT02705664)
- Testing
- Loceryl Nail Lacquer, Urea Ointment, Bifonazole Cream
- Where
- Iceland
- Volunteers
- 22 people
- Sponsor
- Galderma R&D
Acne
Efficacy and Safety of CD5024 1% in Acne Vulgaris
Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week…
- Trial name
- NCT03034460
- Testing
- CD5024 1% cream, CD0271/CD1579 gel
- Where
- 7 sites in Canada, France and 1 more
- Volunteers
- 70 people
- Sponsor
- Galderma R&D
Canthal Lines
A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)
This double-blind study has two parts for each subject (same population): Part A: initial treatment in Lateral Canthal Lines (LCL) (placebo-controlled): To assess the efficacy and safety of Azzalure® compared to placebo in the…
- Trial name
- NCT01308060
- Testing
- Botulinum Toxin Type A
- Volunteers
- 335 people
- Sponsor
- Galderma R&D
Prurigo Nodularis
Safety and Efficacy of Nemolizumab in PN
The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.
- Trial name
- NCT03181503
- Testing
- CD14152 Dose A
- Where
- 16 sites in Austria, France and 2 more
- Volunteers
- 70 people
- Sponsor
- Galderma R&D
Acne Vulgaris
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
- Trial name
- NCT02189629
- Testing
- CD5789 (trifarotene)
- Where
- 32 sites in United States, Czechia and 2 more
- Volunteers
- 453 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
- Trial name
- NCT02566369
- Testing
- CD5789 (trifarotene) 50μg/g cream
- Where
- 124 sites in United States, Canada and 3 more
- Volunteers
- 1,208 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
- Trial name
- NCT02556788
- Testing
- CD5789 (trifarotene) 50µg/g Cream
- Where
- 81 sites in United States, Czechia and 6 more
- Volunteers
- 1,212 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
- Trial name
- NCT03100344
- Testing
- Nemolizumab
- Where
- 67 sites in United States, Australia and 4 more
- Volunteers
- 226 people
- Sponsor
- Galderma R&D
Acne
A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients
Exploratory, international, multi-centre, randomized, investigator blinded study in acne
- Trial name
- NCT01688531
- Testing
- CD0271 0.1%/CD1579 2.5% gel, CD0271 0.1%/CD1579 2.5% gel vehicle
- Where
- 3 sites in Canada, France
- Volunteers
- 38 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
The study hypothesis are based on the assumption that : CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects CD0271…
- Trial name
- NCT01880320
- Testing
- CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
- Where
- 31 sites in United States, Canada
- Volunteers
- 503 people
- Sponsor
- Galderma R&D
Psoriasis
Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis
This study is to evaluate the efficacy and safety of topical application of NP000888 ointment compared to vehicle in plaque and fingernail psoriasis subjects. Duration of administration: 24 weeks
- Trial name
- NCT02995473
- Testing
- NP000888, Vehicle
- Where
- 10 sites in Taiwan
- Volunteers
- 61 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.
This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients.
- Trial name
- NCT02073461
- Testing
- CD1579 2.5%, CD1579 5%, Vehicle
- Where
- 6 sites in Japan
- Volunteers
- 236 people
- Sponsor
- Galderma R&D
Acne Vulgaris
A Long Term Study of GK530G in Subjects With Acne Vulgaris
This open label study is to determine the safety profile of GK530G in a long-term treatment (up to 12 months) in subjects with acne vulgaris and to evaluate the efficacy of GK530G in a long-term treatment.
- Trial name
- NCT01910064
- Testing
- GK530G
- Where
- 16 sites in Japan
- Volunteers
- 436 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12…
- Trial name
- NCT02073448
- Testing
- GK530G, CD0271, CD1579
- Where
- 13 sites in Japan
- Volunteers
- 417 people
- Sponsor
- Galderma R&D
Rosacea
Effect of CD07805/47 Gel in Rosacea Flushing
Phase 2a study to assess the efficacy and safety of CD07805/47 0.5% gel in the prevention of the flush of rosacea.
- Trial name
- NCT02300129
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Study objectives: To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea after 16-week topical treatment.
- Trial name
- ATTRACT (NCT01493947)
- Testing
- Ivermectin 1% cream, Metronidazole 0.75% cream
- Where
- 60 sites in Bulgaria, Czechia and 8 more
- Volunteers
- 962 people
- Sponsor
- Galderma R&D
Rosacea
Rosacea Prevalence in General Population - Pilot Study
The purpose of this study is to test and refine, a subject questionnaire aimed to be used in a general population rosacea prevalence study.
- Trial name
- NCT02292836
- Testing
- Questionnaire testing
- Where
- 2 sites in Canada, Sweden
- Volunteers
- 120 people
- Sponsor
- Galderma R&D